The provided text provides a detailed summary of Thermo Fisher Scientific Inc.'s condensed consolidated financial statements, including balance sheets, income statements, statements of comprehensive income, and cash flows, among other relevant financial information. It also discusses the company's financial assets and liabilities, including debt instruments, fair value measurements, and financial derivatives. Additionally, it covers topics like earnings per share, income taxes, commitments, and contingencies related to environmental matters and litigation. The information also includes information on comprehensive income, fair value of financial instruments, supplemental cash flow information, and restructuring and other costs within the company.
The text provided is a comprehensive Management's Discussion and Analysis of Financial Condition and Results of Operations from Thermo Fisher Scientific Inc. The company provides forward-looking statements regarding financial conditions and operations, detailing factors that could affect results, such as the impact of COVID-19 and acquisitions. The text reports financial highlights, segment performance, organic revenue growth, recent acquisitions, non-operating items like interest expense and tax rates, liquidity, and capital resources. It also explains non-GAAP measures used, such as adjusted operating income and EPS, and provides information on free cash flow. Additionally, critical accounting policies, estimates, and recent accounting pronouncements are covered. The discussion includes detailed financial data and explanations of varied financial aspects and metrics of the company.
The company's exposure to market risk from changes in interest rates and currency exchange rates has not significantly changed since its last annual report for the year ended December 31, 2021.
The company's management, including the CEO and CFO, evaluated the effectiveness of disclosure controls and procedures as required by the rules under the Exchange Act. They concluded that at the end of the reporting period, the company's controls and procedures were effective at the reasonable assurance level. There were no significant changes in the company's internal control over financial reporting during the fiscal quarter.
The text provided discusses the presence of legal proceedings against a company, encompassing matters related to product liability, intellectual property, employment, and commercial issues. These legal challenges are detailed in "Note 8 to our Condensed Consolidated Financial Statements – Commitments and Contingencies."
The text mentions that material risks for investors are outlined in the company's Annual Report on Form 10-K for the year ended December 31, 2021, under the section named "Risk Factors," which is available for review with the SEC.
No shares of the company were repurchased during the second quarter of 2022. The Board of Directors had authorized the repurchase of up to $3 billion of the company's common stock on September 23, 2021. As of July 2, 2022, $1 billion was still available for future repurchases under this authorization.
Please provide the text for summarization.
I am ready to help you with summarizing the text whenever you're ready.
I will wait for all the parts of the text before summarizing it.
The text provides a list of exhibits related to certifications, XBRL documents, and other filings required by the Securities Exchange Act of 1934. It includes certifications from the CEO and CFO, XBRL taxonomy extension documents, and a cover page interactive data file. The exhibit also details the agreement to furnish long-term debt instruments upon request. The text concludes with signatures from the Senior Vice President and Chief Financial Officer, as well as the Vice President and Chief Accounting Officer of Thermo Fisher Scientific Inc.
